11 news items
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL
6 May 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
OCUL
6 May 24
of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
OCUL
3 May 24
"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
OCUL
1 May 24
"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
OCUL
18 Apr 24
vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD
khwww72356x
OCUL
16 Apr 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
tir7z3ig9378plw4m1gy7cb8gqkyg1dwii6sxibu1o 1hd2ikyz
OCUL
15 Apr 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet
uvhvtufto68gt3ctchh6xm8b3w3kbunspu88kko jwzukmpuy1q
OCUL
9 Apr 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
tzpz73v8d1pl3ys4wtuwm uee0dkrqbd9vbgn8mnb4hkjezrghixx5j
OCUL
6 Apr 24
"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
h0q3byn1ujtumh5i6geefoyb1qj5jaducv0ner06rz0u9ysa2j3opy5
OCUL
26 Mar 24
of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced
b2f2ec2sa6ak0s32iujiqkok74bbgdoac31x95gx9iikcqa5kybr
OCUL
5 Mar 24
of innovative therapies for retinal disease and other diseases and conditions of the eye, today announced plans to report the Company's fourth quarter and full
- Prev
- 1
- Next